Loading clinical trials...
Loading clinical trials...
Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study
Conditions
Interventions
Botulinum Toxin A
Placebo
+1 more
Locations
1
United States
Tennessee Clinical Research Center
Nashville, Tennessee, United States
Start Date
April 29, 2019
Primary Completion Date
December 4, 2019
Completion Date
December 22, 2020
Last Updated
June 5, 2025
NCT05481931
NCT06411002
NCT05146999
NCT05894109
NCT05148000
NCT05277337
Lead Sponsor
Croma-Pharma GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions